IMI RAPID-COVID PROJECT
During this 15-month project, the consortium aims to analytically and clinically validate (CE mark) a test that can simultaneously detect and differentiate SARS-CoV-2 as well as 16 other common respiratory diseases (bacteria and viruses).
Everything will be automated on our ACSIA platform.
Ultimately, this technology will provide maximum flexibility in screening and triage, enabling better and faster care, relieving pressure on healthcare systems and improving patient recovery rates.
This project received funding from the Innovative Medicines Initiative Joint Undertaking (JU) 2 under Grant Agreement No 101005144. The Joint Undertaking receives support from the research program and Horizon 2020 innovation from the European Union and EFPIA.